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Abstract
Background: European Regulation 1924/2006 states that all health claims made on foods need to be
substantiated scientifically.
Objective: To apply the PASSCLAIM criteria for the scientific substantiation of health claims on foods to
herbal supplements containing Ginkgo biloba. Evaluation of three selected claimed health effects for G. biloba
(improvement of blood circulation, improvement of symptoms of old age, and improvement of memory) was
achieved through review of publicly available scientific data. A total of 35 human intervention studies were
evaluated. Commercially available products claimed to contain mainly G. biloba (N29) were randomly
sampled in the Netherlands and analyzed for their content on ginkgo extract. Also, a toxicological risk
assessment was performed.
Results: The three selected health claims investigated could not be substantiated. This was mainly because of
a lack of data from studies in healthy volunteers. In most studies results performed with a 24% standardized
G. biloba extract were described. However, our chemical analysis showed that 25 of the 29 sampled products
did not contain the required minimum 24% standardized extract. Moreover, in most preparations the content
of substances typical for G. biloba did not conform to what was declared on the label. Since toxicity data for
G. biloba are very limited, a safety limit could not be established.
Conclusions: Evidence is lacking for three health claims of herbal products with G. biloba. Neither safety nor
efficacy can be guaranteed at the recommended daily dose. The multidisciplinary approach described in this
paper provides good insight into issues that are relevant for the evaluation of health claims for herbal food
supplements.
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T
he European Regulation 1924/2006 on nutrition
and health claims made on foods states that health
claims made on foods, including functional foods
and dietary supplements, have to be scientifically sub-
stantiated (1). Articles 5.1.a and 6 state that generally
accepted scientific evidence is needed for this. An over-
view of the new European Regulation for health claims
has recently been published (24). In short, reduction of
disease risk claims and claims referring to children’s
development and health are accounted for in Articles 14
and 13.5, and require to be reviewed separately by the
European Food Safety Authority (EFSA). A complete
dossier containing details of all studies pertinent to
the proposed claim is required for an application under
Article 14 of the Health Claim Regulation and should be
supplied to EFSA via one of the EC member states.
EFSA will assess these health claims on a case-by-case
basis, leading to an authorization by the European
Commission (2, 4, 5). Health claims other than Article
14 and 13.5 claims, the so-called ‘generic claims’ are
accounted for in Article 13.1. These claims are based on
‘generally accepted scientific evidence.’ For these ‘generic
claims,’ no complete dossier per claim is required (6), and
similar applications can be evaluated in batches. The
European Commission aimed to adopt a Community
list of permitted claims by 31 January 2010, but this
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of proposals for health claims submitted (2).
To help manufacturers with their preparation and
submissionofArticle14healthclaims(reductionofdisease
risk claims and claims referring to children’s development
andhealth)and13.5healthclaims(basedonnewscientific
developments), in July 2007, EFSA published a guidance
document ‘Scientific and technical guidance for the pre-
paration and presentations of the application for author-
ization of a health claim’ (2, 7). The document specifies
what information manufacturers have to include in their
application, in particular, with regard to the scientific data
that is needed (7). Criteria for the scientific substantiation
ofhealthclaimsonfoodsweredevelopedfrom2001to2005
intheEU-sponsoredPASSCLAIMproject(8,9)andthese
were taken into account in setting down the EFSA
guidance. According to these criteria, a comprehensive
review of human studies on the relationship of the food or
nutrient to the claimed health effect is systematically and
transparentlyundertakenbeforeadecisioncanbemadeon
the claim. Human studies are considered pertinent to the
claim. Data of animal or in vitro studies can be used as
supportingevidence.Thetotalityofscientificdataneedsto
be included and then the evidence needs to be weighed.
Blinded placebo-controlled trials in healthy human sam-
ples carry most weight.
The project described in this paper applies the
PASSCLAIM criteria for scientific substantiation of
health claims on foods to herbal supplements containing
Ginkgo biloba, which were used as a model. This paper is
largelybasedonaRIVMreportinDutchfrom2007which
was posted on the RIVM website only (http://
www.rivm.nl/bibliotheek/rapporten/320106001.html).
Uponmanyrequeststohavethisreportalsoavailableinthe
English scientific literature, we have written the current
version. We have not changed the conclusions of the
original report, but we have updated the literature and
developments where applicable.
G. biloba originates from the G. biloba tree. For
herbal supplements, usually a G. Biloba leaf extract is
used, although the seeds can also be used in dietary
supplements. However, in the scientific literature, only
effects of the standardized leaf extract are supported (10).
A standardized leaf extract (GB-STE; extract of dry
G. biloba leaves with acetone and water) contains 2227%
of flavone glycosides and 57% of terpene lactones, with
2.83.4% of ginkgolide A, B, and C, and 2.63.2% of
bilobalide (Table 1). The concentration of ginkgolic acid
(GAS)needstobebelow5ppminaGB-STE(11).Thetwo
most considered GB-STEs in studies areEGb761 (12) and
LI 1370. AWHO monograph indicates the use of G. biloba
extract for symptomatic treatment of mild to moderate
cerebrovascular insufficiency, improvement of pain-free
walking distance in patients with peripheral arterial
occlusive disease (PAOD), and treatment of inner ear
problemsliketinnitus(11).Thesearenothealthclaimsbut
medical claims, which are prohibited on foods and food
products(1).InGermany,CommissionEhasapprovedthe
use of G. biloba for the same three indications (13).
A random checkon the existence and qualityof files for
substantiation of claims on herbal supplements of the
Dutch Food and Consumer Product Safety Authority in
2003 showed that the claim substantiation process was
unsatisfactory for herbal supplements in general (14). The
outcomeofthatstudyresultedinthisevaluationstudy.The
aims of the current study were threefold: (a) analysis
of herbal supplements containing G. biloba (N29)
randomly sampled in Dutch shops by the Dutch Food
and Consumer Product Safety Authority (VWA); (b)
scientific substantiation of three selected claimed health
effects of G. biloba (including effective dose of substances
typical for G. biloba, if available) through an overview of
publiclyavailable,scientificdata;and(c)riskassessmentof
G. biloba and, if possible, derivation of a level for safe use.
Methods
Product analysis
In August and September 2005, 29 G. biloba food
supplements were sampled in the Netherlands. An
inventory was made of the indications for use as stated
on the label. Claims for a positive influence on memory
and/orconcentration or improvement of bloodcirculation
were most frequently mentioned. Only four products
didn’t have any claims on the label (see Table 2).
To determine the degree to which the content of the
substances typical for G. biloba were analog to what was
declared on the label, the main components of G. biloba,
flavone glycosides (also known as flavonoids), and terpene
lactones were analyzed. Flavone glycosides were analyzed
by using high-pressure liquid chromatography (HPLC)
according to the method of Mesbah et al. (15), but with
an extra hydrolysis step added to the pretreatment step.
Without this hydrolysis step, no flavonoids were detected
in the samples. Terpene lactones were analyzed using
Table 1. Substances typical for Ginkgo biloba
Substance
Specification of
substance
Included in standardized
leaf extract (e.g. EGb761
or LI1370)
Flavone glycosides Quercetin
Kaempferol
Isorhamnetin
2227% flavone glycosides
Terpene lactones Ginkgolide A
Gingkolide B
Ginkgoblide C
Bilobalide
57% terpene lactones
(2.83.4% ginkgolide A, B,
C, 2.63.2% bilobalide)
Ginkgolic acid Below 5 ppm
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Product
No. Declaration on the label
Recommended
daily dose
Analyzed amount of
terpene lactones
(mg/daily dose)
Meets criterion for
terpene lactone levels
in standardized
extract? (617 mg)
Analyzed amount
of flavonoids
(mg/daily dose)
Meets criterion for
flavonoid levels in
standardized extract?
(2465 mg)
Meets criteria for
terpene lactones and
flavonoid levels in
standardized extract
(based on daily dose)
Claims present
on the label
7966 Ginkgo biloba extract-24%
180 mg/capsule
11 capsule 10.1 Yes 38.4 Yes Yes Yes
7967 Ginkgo biloba extract (24%) 112 capsules 2.8 No 12.9 Yes, only at
maximum dose
No Yes
7968 Ginkgo biloba extract (24%
Ginkgo flavoglysides6%
terpene lactones)
60 mg/capsule
12 capsules 4.5 Yes 16.1 Yes Yes Yes
7969 Ginkgo biloba 32 capsules 0.9 No 0.3 No No Yes
7970 Ginkgo biloba folia
80 mg/tablet
11 capsule 1.3 No 3.5 No No Yes
7971 Extract from fresh leaves
of Ginkgo biloba (7.5%
flavoglycosides)
40.5 mg/coated tablet
312 tablets 1.4 Yes, only at
maximum dose
4.0 No No Yes
7972 Ginkgo biloba extract.
Standardized extract at least
24% ginkgosides6% terpene
lactones
120 mg/2 capsules
21 capsule 5.9 Yes 12.4 Yes Yes No
7973 Ginkgo biloba
96 mg/capsule
31 capsule 0.3 No 2.3 No No Yes
7974 Ginkgo biloba, 50%
100 mg/tablet
31 tablet 0.3 No 0.9 No No Yes
7975 Standardized Ginkgo biloba
extract (50:1), 24% ginkgo
flavoglycosides of 3,000 mg
fresh plant 60 mg/capsule
113 capsules 3.5 Yes, only at
maximum dose
13.1 Yes, only at
maximum dose
Yes, only at
maximum dose
No
7976 Ginkgo biloba 31020 droplets 0.5 Yes NA NA Unknown Yes
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Product
No. Declaration on the label
Recommended
daily dose
Analyzed amount of
terpene lactones
(mg/daily dose)
Meets criterion for
terpene lactone levels
in standardized
extract? (617 mg)
Analyzed amount
of flavonoids
(mg/daily dose)
Meets criterion for
flavonoid levels in
standardized extract?
(2465 mg)
Meets criteria for
terpene lactones and
flavonoid levels in
standardized extract
(based on daily dose)
Claims present
on the label
7977 Ginkgo biloba extract.
Standardized on 24%
flavoglycosides and 6%
terpene lactones of 10,000 mg
dried leave 200 mg/capsule
11 capsule 3.3 No 45.4 Yes No Yes
7978 Ginkgo biloba leaf extract
(50:1 extract with 24% ginkgo
flavon glycosides) 60 mg/caps
131 capsule 6.2 Yes 20.1 Yes, only at
maximum dose
Yes, only at
maximum dose
Yes
7979 Ginkgo biloba
26 mg/tablet
31 tablet 3.0 Yes 7.0 No No Yes
7980 Ginkgo biloba 2425 droplets 0.1 No NA NA No Yes
7981 Ginkgo biloba standard
extract (24% ginkgo
flavoglycosides, 6% terpene
lactones)
80 mg/tablet
11 tablet 1.8 No 20.7 No No Yes
7982 100% Ginkgo biloba
concentrate
342030
droplets
0.3 Yes, only at
maximum dose
NA NA Unknown No
7983 Ginkgo biloba folia. (min 24%
ginkgoflavon glycosides and
6% ginkgo terpene lactones)
120 mg/3 capsules
31 capsule 4.4 Yes 10.2 Yes Yes No
7984 Ginkgo biloba extract (leaf)
250 mg/capsule
312 capsules 2.0 Yes, only at
maximum dose
8.0 Yes, only at
maximum dose
Yes, only at
maximum dose
Yes
7985 100 ml, bevat liquid extract
of Ginkgo biloba (folia) 40%
3040 droplets 0.1 No NA NA No Yes
7986 Ginkgo biloba (dries leaf)
250 mg/tablet
31 tablet 0.8 No 1.9 No No Yes
7987 Ginkgo biloba (dried leaf,
standardised on 24% ginkgo
flavon glycosides 14.4 mg and
6% terpenes 3.6 mg)
60 mg/tablet
121 tablet 5.3 Yes, only at
maximum dose
16.0 Yes, only at
maximum dose
Yes, only at
maximum dose
Yes
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Product
No. Declaration on the label
Recommended
daily dose
Analyzed amount of
terpene lactones
(mg/daily dose)
Meets criterion for
terpene lactone levels
in standardized
extract? (617 mg)
Analyzed amount
of flavonoids
(mg/daily dose)
Meets criterion for
flavonoid levels in
standardized extract?
(2465 mg)
Meets criteria for
terpene lactones and
flavonoid levels in
standardized extract
(based on daily dose)
Claims present
on the label
7988 Ginkgo biloba (leaf)
standardized on 0.5%
flavonoides 250 mg/capsule
31 capsule 1.1 No 2.1 No No Yes
7989 Ginkgo biloba (24% extract:
24% flavoglycosides and 6%
terpenes) 60 mg/capsule
31 capsule 4.8 Yes 15.1 Yes Yes Yes
7990 Ginkgo biloba (24% extract)
50 mg/capsule
11 capsule 4.0 No 50.1 Yes No Yes
7991 Ginkgo biloba extract
(24% flavonoiden, 6% terpene
lactones) 300 mg/2 capsules
12 capsule 5.0 Yes 42.9 Yes Yes Yes
7992 Ginkgo biloba (folia) dried
extract (standardized on 24%
flavon glycosides / 6% terpene
lactones), max 5 ppm ginkgo
acids 30 mg/tablet
112 capsules 2.7 No 7.6 No No Yes
7993 Ginkgo biloba extract
10 mg/tablet
112 tablets & No 4.0 No No Yes
7994 Ginkgo biloba extract
(24% flavonoides, 6% terpene
lactones)
300 mg/2 capsules
12 capsules 3.3 Yes 35.3 Yes Yes Yes
8410 Extract 24% (9.6 mg
flavonoides, 2.4 mg terpene
lactones)
40 mg/ tablet
31 tablet 2.2 Yes 9.0 Yes Yes No
Note: NA, not analyzed (method not suitable); &, not present.
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)HPLC with refractive index-detection (RI), also based on
the method of Mesbah et al. (15), but with RI-detection
instead of the UV-detection, because UV-detection leads
to interfering peaks. Reference material included a
standardized 24% extract and Tavonin† (16, 17). The
Dutch guideline ‘Besluit Geneesmiddelen Wet’ (18) states
that the amount of the active substance present in a
pharmaceutical product has to be 90110% of the
declared amount. To prove the presence of a 24%
standardized G. biloba extract in the products, the amount
of bilobalide compared to the total amount of terpene
lactones was calculated. A ratio of 3959% was used
as a reference, corresponding to the ratio used in the
European Scientific Cooperative On Phytotherapy
(ESCOP) monograph (19).
Health claim substantiation
Three commonly encountered claimed health effects for
G. biloba were selected: improved blood circulation,
effects on symptoms of old age, and improved memory.
Examples of such claims used are: ‘helps for cold hands
and feet; improves memory; protects against symptoms of
old age; natural memory booster.’ Per health effect a
literature search was conducted in publicly available,
objective scientific data:
. reference and text books and monographs, e.g.
ESCOP and WHO (11, 19);
. scientific articles, with the emphasis on human studies,
searched via PubMed, Toxline, Cochrane Library, and
references from articles, in Dutch and English. Search
terms used were: ginkgo; Ginkgo biloba; LI 1370;
EGb761; meta-analysis; review; randomized con-
trolled trial; viscosity; microcirculation; blood flow;
elderly; symptoms of old age; cognition; cognitive
function; and memory.
An overview of the available literature per health effect
can be found in Table 3, including not only studies in
healthy volunteers (n24), but also some important
patient studies (n11). The PASSCLAIM criteria were
applied to assess if the health claims can be supported
by the totality of the data and weighing of the evidence
(8). The criteria are that the product needs to be
characterized and administered in amounts consistent
with its intended consumption. Studies should include
representative human study groups, have appropriate
controls, an adequate study duration, characterized
background diets, and monitor compliance of the study
group. The target variable should change in a statistically
significant way and the change should be biologically
meaningful for the target group. Dependent on the
quality of the data, per health claim a conclusion was
drawn as to the substantiation of the claim with reference
to the strengths and weaknesses therein.
Toxicity
Information on toxicity of G. biloba was obtained
by searching literature databases (Medline, PubMed,
Toxline), international documentation (Commission E
monograph, ESCOP monograph, Hager’s Handbuch,
European Medicines Agency  EMEA  information on
animal drugs, CBG  College ter Beoordeling van
Geneesmiddelen  [Dutch Medicines Evaluation Board]
information on drugs, WHO, Herbalgram information,
National ToxicologyProgram NTP),andtheinternet.In
the Commission E monograph, ESCOP monograph, and
Hager’s Handbuch, toxicity of the standardized extract
EGb761isdescribed.Thetoxicityevaluationinthecurrent
evaluation is based on those reports aswell as recent NTP
studies and recent literature, predominantly case reports,
andreportsoninteractionwithfrequently/commonlyused
medication. In addition to G. biloba and the GB-STE,
data on GAS were considered for evaluation. Because of
their toxic properties, the presence of GAS is limited in
standardized G. biloba preparations to maximum 5 ppm
(11).However,innon-standardizedG.bilobapreparations,
GAS can be present at higher levels.
Results and discussion
Product analysis
For 16 products, both the detailed content and the
recommended dose were declared on the label (see
Table 2). For 13 products, the declaration was unclear,
e.g. the recommended dose was stated, but the amount of
flavonoids and terpene lactones in this dose was not
stated in the declaration. Only two of the 29 products met
the pharmaceutical guideline (the amount present in the
product is 90110% of the declared amount) for terpene
lactones. For flavonoids, seven out of the 29 products met
the guideline. Only one product met the guideline for
both components. Only four products met the criteria of
a ratio of 3959% (the amount of bilobalide compared
to the total amount of terpene lactones). Based on the
daily dose and the concentration of terpene lactones
and flavonoids found in the products, a dose range
of substances typical for G. biloba was calculated;
16 products did not meet the dose range for terpene
lactones and flavonoids for a 24% standardized extract.
In summary, when the components of herbal
supplements were evaluated according to the guideline
for pharmaceuticals, that require the presence of 90110%
of the declared amount, one out of 29 G. biloba products
meets the guideline.
1 The amount of terpene lactones
and flavonoids found vary between 27358% for
terpene lactones and between 86418% for flavonoids.
1 The guideline for pharmaceuticals (18) was used because no
alternative guidelines for herbal supplements were available.
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Intermediary of health effect References
Specification Ginkgo bilobadose
(PASSCLAIM criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population
(N, age group)
(PASSCLAIM criteria
2A2B)
Information on background
diet, matrix and compliance?
(PASSCLAIM criteria
2D2F2G)
Blood circulation: patient studies
Intermittent claudication Nicolai et al. (23) Standardized Ginkgo biloba extract,
in most studies EGb761
Meta-analysis; 14 randomized,
controlled trials
Patients (18 years and
older) with intermittent
claudication, stage II
according to Fontaine,
stages 13 according to
Rutherford
For some studies
information is included
Peripheral arterial occlusive
disease (PAOD)
Horsch and Walther (21) EGb761; daily dose: 120 mg (five
studies) or 160 mg (four studies);
study period: 16 weeks,
13 months, 66 months
Meta-analysis; 9 clinical trials,
randomized, double-blind,
placebo-controlled.
Total 619 patients criteria:
randomized, double-blind,
placebo-controlled, clinical studies,
oral application form of EGb761,
assessment of pain-free walking
distance.
Patients with the indication
peripheral arterial occlusive
disease (PAOD) in stage II
according to Fontaine
No information
Intermittent claudication Pittler and Ernst (22) Ginkgo biloba extract, 3EGb761,
other studies GB extract not further
specified daily dose: 5120 mg;
3160 mg
Study period: 16 weeks,
112 weeks, 624 weeks
Meta-analysis, 8 studies.
Inclusion criteria: randomized,
double-blind, placebo controlled, no
combination with other medications
or remedies, assess walking
distance, no language restrictions.
Methodologic quality assessed
by scoring system.
Patients with intermittent
claudication (n415),
categorized according to
the Fontaine criteria.
No information
Cerebral insufficiency Hopfenmuller (82) Mostly used of 150 mg/day
Ginkgo biloba extract (LI1370)
Meta-analysis 8 placebo controlled,
randomized double-blind studies
(out of 11). Studies were
comparable with regard to
diagnoses, inclusion and exclusion
criteria and methodology.
Elderly patients (2163 to
5580 year); with cerebral
insufficiency; in- and
exclusion criteria
comparable.
No information
Table 3. Studies included
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)Table 3a (Continued)
Intermediary of health effect References
Specification Ginkgo bilobadose
(PASSCLAIM criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population
(N, age group)
(PASSCLAIM criteria
2A2B)
Information on background
diet, matrix and compliance?
(PASSCLAIM criteria
2D2F2G)
Cerebral insufficiency Kleijnen and Knipschild (24) EGb 761
(24% gingko-flavone
glycosides, 6% terpenoids);
LI 1370
(25% ginkgo-flavone
glycosides, 6% terpenoids).
There may be differences in
composition of preparations
depending on manufacturing
process used.
In most trials, 120160 mg/day,
divided in three doses, was used;
6 weeks to 12 months.
Systematic review eight randomized
double-blind, placebo-controlled
human studies (out of 40),
investigating the utility of Ginkgo
Biloba for ‘cerebral insufficiency.’
Patients aged 50 with
mild to moderate
symptoms of cerebral
insufficiency (indication and
duration of symptoms
specified if known).
No information
Memory improvement: studies in healthy volunteers
Cognitive function in healthy
subjects
Canter and Ernst (87) Standardized Ginkgo biloba extracts:
EGb761 (24% flavonoid glyco,
6% terpene lactones)
GK501 (24% flavo, 6% terpene)
LI1370 (27% flavo, 7% terpene)
Ginkgo biloba forte (24% flavo,
6% terpene)
At different dose
Review: of placebo-controlled
double-blind trials: 9 trials, mainly
short term (130 days). (literature
search to Nov 2001)
Healthy subjects with no
diagnosed relevant medical
condition, mean age
B60 year,
EXCLUDING subjects with
age-related memory
impairment or ‘cerebral
insufficiency.’
No information
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Intermediary of health effect References
Specification Ginkgo bilobadose
(PASSCLAIM criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population
(N, age group)
(PASSCLAIM criteria
2A2B)
Information on background
diet, matrix and compliance?
(PASSCLAIM criteria
2D2F2G)
Memory improvement: patient studies
Cognitive decline/dementia Birks et al. (28) (updated in
2007 and 2009 (30, 32)
All but one study * used a Ginkgo
preparation based on the standard
extract (24 mg flavone glycosides,
6 mg ginkgolides/100 mg); daily dose:
80600 mg/day (usually B 200).
Meta-analysis 33 included studies:
unconfounded, randomized,
double-blind controlled;
duration 352 weeks (majority
12 weeks) update 2009:
36 included trials
People with acquired
cognitive impairment,
including dementia, of any
degree of severity.
Excl: other serious illnesses,
other mental illnesses,
illness that can cause the
memory problems; many
excluded people with a
history of abuse of alcohol,
drugs, or medication. Most,
but not all studies excluded
patients on vasoactive
drugs, antipsychotics,
neuroleptics, cholinergic,
antidepressants.
No information
Alzheimer disease Oken et al. (98) EGb761 and Tanakan daily dose:
120240 mg
Study duration:
122426 weeks
Meta-analysis of 4 studies inclusion
criteria: sufficiently characterized
patients with diagnosis of Alzheimer
disease; clearly stated study
exclusion criteria for depression,
other neurologic disease, central
nervous system-active medications;
use of standardized ginkgo extract;
randomized placebo-controlled,
double-blind study design; at least
one objective assessment of
cognitive function as outcome
measure; sufficient statistical
information
Patients with a diagnosis
of Alzheimer disease, by
criteria;
N424 (212 ginkgo group,
212 placebo group)
Use of central nervous
system-active medications
excluded
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Nicolai et al. (23) Absolute claudication distance (ACD) at end of study
(available in 11 trials (N477)).
Increase of 64.5 metres (1.8130.7, non-significant)
of GB treatment vs. placebo at the end of the study
periods.
Conclusion authors: the clinical relevance of a non
significant improvement of 64.5 metres in ACD is
questionable. It was concluded that Ginkgo biloba has no
significant effect on walking distance in people with
intermittent claudication.
Horsch and Walther (21) Ratio of the walking distance between EGb761 and
placebo
Duration studies: 6 months, as required by guidelines
(8); 3 months and 6 weeks (1):
Pooled estimator of the ratio1.23 (1.161.31)
improvement in pain-free walking distance 34 and 33 m;
this equals an increase of at least 30% compared to man
values at baseline, results are clinically relevant
according to study guidelines.
Conclusion authors: this review confirms the efficacy of
EGb761. It demonstrates statistical significance of the
difference with respect to placebo and clinical relevance
for the treatment of PAOD patients.
Comment: high variability between study designs, study
conditions and centers within each study.
Pittler and Ernst (22) Pain-free walking distance: defined using devices that
forced the patients to walk at a set speed.
Duration of studies: 624 weeks 7/8 trials: weighted
mean differences that favored GB compared to placebo,
4/8 trials significant differences.
Statistical pooling: significant difference in the increase
in pain-free walking distance GB compared to placebo:
weighed mean difference 34 meters (95% CI 2643)
Conclusion authors: results suggest that Ginkgo biloba
extract is superior to placebo in the symptomatic
treatment of intermittent claudication.
Overall effects seem modest, of uncertain clinical
relevance, no final judgment on the efficacy of this
treatment.
Comment: only one trial reported the randomization
procedure that was used.
Hopfenmuller (82) Symptom improvement ginkgo compared to placebo.
Symptoms among others: headache, tinitus,
concentration, dizziness, fear, bad memory,
forgetfulness
For all analyzed single symptoms: sign differences,
superior of ginkgo.
Total of clinical symptoms: seven studies confirmed
effectiveness of ginkgo, one study inconclusive.
Conclusion authors: Therapeutical effectiveness of
Ginkgo biloba regarding the clinical symptoms complex
confirmed.
Kleijnen and Knipschild (24) Different per study, a.o. symptoms, overall assessment
doctor/patient, cognitive test battery, behavioral rating
scale.
All but one trial (of eights investigated) showed positive
effects of Ginkgo biloba compared with placebo on the
symptoms; significant improvements after 12 weeks/
3 months.
Dose: 112160 mg/day.
Conclusion authors: therapy is warranted for patients
with mild to moderate cerebral insufficiency, but further
studies are needed, with larger numbers of patients;
treatment must be for 46 weeks before positive effects
can be expected. Differences are large enough to be
clinically relevant.
Comment: only 8 out of 40 studies were well performed.
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Canter and Ernst (87) Objective and/or subjective outcome measures of
cognitive function (excl studies which measure only
neurophysiological parameters such as EEG).
Different outcome measures, e.g. Sternberg, Critical
Flicker Fusion, Choice Reaction Time, LARS, Image
recognition, Image free-recall, CDR test battery, speed of
attention, immediate word recall, Stroop test.
In the single-dose and medium-term studies stat sign
positive effects are largely confined to one or at most
two tests from a larger battery of tests. All of these
trials failed to report subjective effects of the extract.
A positive subjective effect was reported only in the
longest trial.
Conclusion authors: there is no sufficient evidence to
advocate Ginkgo for cognitive enhancement in healthy
populations, the effects reported in these trials are few
and inconsistent. Need for long-term trials with healthy
subjects. The use of Ginkgo biloba as a ‘smart’ drug
cannot be recommended on the basis of the evidence
available to date.
Birks et al. (28) (updated in
2007 and 2009 (30, 32)
  GCI scale by physician
  Cognition, change from baseline
  ADL
  Mood and emotional function
Doses below and above 200 mg/day and the different
treatment times of B12 weeks, 12 weeks, 24 weeks, 52
weeks, are analyzed separately
CGI scale (dichotomized)
Benefits associated with Ginkgo biloba at dose
B200 mg/day, duration B12 weeks: OR
15.32 (5.9039.80) pB0.0001;
and dose  200 mg/day, duration 24 weeks: OR
2.16 (1.114.20) p0.02.
Cognition
Benefit for ginkgo compared with placebo at
12 weeks (B200 mg and  200 mg), 24 weeks (all
doses), 52 weeks (B200 mg/day).
ADL
Benefit for ginkgo compared with placebo at
B12 weeks (dose B200), 24 weeks (dose B200),
52 weeks (dose B200)
Mood and emotional function
Benefit for ginkgo at B12 weeks, dose B200 mg/day
12 weeks, dose B200 mg/day
24 weeks, dose B 200 mg/day
Conclusion authors: overall there is promising evidence
of improvement in cognition and function with ginkgo.
However, three more modern trials show inconsistent
results. There is need for more trials to confirm the
efficacy
*new preparation, Geriaforce, was used, ethanolic extract
of ginkgo leaves (1:4), contains 0.20 mg/ml flavone
glycosides, 0.34 mg/ml ginkgolides.
Update 2009: three more trials included. Conclusion
authors: ‘Many of the early trials used unsatisfactory
methods, were small, and publication bias cannot be
excluded. The evidence that Ginkgo biloba has
predictable and clinically significant benefit for people with
dementia or cognitive impairment is inconsistent and
unreliable.’
Oken et al. (98) Objective measures of cognitive function in Alzheimer
disease.
SKT (syndrome-Kurztest), choice reaction time,
ADAS-cog, 10-item battery (incl Benton Visual Retention
Test, digit symbol, word list recall, and reaction time),
mini-mental state examination (MMSE), kendrick digit
copying and object learning tasks, digit recall,
classification task.
Overall significant effect size of 0.40, pB0.0001.
This modest effect size translated into a 3% difference
in the ADAS-cog.
Conclusion authors: small but significant effect of
36-month treatment with 120240 mg of Ginkgo biloba
extract. The clinical significance of this effect size is less
clear.
Further research in the area will need to determine if
there are functional improvements and to determine the
best dosage.
Comment: only four studies met inclusion criteria, out of
57. Almost all studies reported positive effects, majority
for ‘cerebral insufficiency,’ if this diagnosis was not further
specified, article was not included.
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)Table 3b. Original studies
Intermediary of
health effect References
Specification Ginkgo biloba
 dose (PASSCLAIM
criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population (N, age group)
(PASSCLAIM criteria 2A2B)
Information on background diet,
matrix, and compliance?
(PASSCLAIM criteria 2D2F2G)
Blood circulation: studies in healthy volunteers
Skin blood flow Boelsma et al. (27) 380 mg/day EGb761
(Tavonin), 3 weeks
Randomized, double-blind,
placebo-controlled, crossover
study, 3 weeks with a 2 week wash
out period
27 Caucasian non-smoking subjects
(10 male, 17 female), aged 5574 years.
Excl criteria: metabolic or endocrine
disease, history of medical or surgical
events (e.g. CVD, skin diseases,
hypertension), anticoagulant therapy
and/or chronic use of vasoactive agents
Use of dietary supplements not allowed,
no alcohol on evening before test day
and on test day, no coffee on test day;
compliance was checked (98%)
Cognitive performance
and blood viscosity
Santos et al. (25) Dried Ginkgo biloba extract,
80 mg/day: 24% flavonoide,
6.1% terpenoide, 2.7%
bilobalide, 1.7% ginkgolide A,
0.9% ginkgolide B, and 0.8%
ginkgolide C
Double-blind, random (except for
matching on education years),
placebo-controlled, independent
group design, 8 months
48 male volunteers, non-demented,
aged 6070 years, with cognitive
abilities within normal range, with
complaints of mild loss of memory.
Excl: psychiatric or neurological
disorders, history of drug addiction or
heavy alcohol drinking, on medication
or drugs that might interfere with
neurological testing.
Patient compliance was controlled by a
number of control procedures,
restriction of drugs and medication that
might interfere with testing.
Forearm
hemodynamics
Mehlsen et al. (81) Ginkgo biloba extract (Gibidyl
Forte), containing 9.6 mg
ginkgoflavonglycoside, 2.4 mg
terpenlactones per tablet,
three times a day for 6 weeks
Randomized, double-blinded
placebo-controlled, cross-over
design
16 healthy subjects, median age 32
years (2147).
Excl criteria: history of neurological,
cardiovascular, pulmonary,
gastrointestinal, hepatic, renal disease,
hypertensive
No information
Memory improvement: studies in healthy volunteers
Cognitive abilities in
healthy adults
Burns et al. (41)
[Included in review
Canter]
Ginkgoforte 120 mg/day
(340 mg): containing per
tablet 40 mg ginkgo extract,
standardized to contain 10.7
mg flavon glycosides (24%)
and 2.7 mg ginkgolides (6%),
12 weeks
12-week double-blind, fixed-dose,
placebo-controlled, parallel groups
design
Study 1: healthy older adults (5579
years, males and females) n93. Study
2: healthy young adults (1843 years)
n104 (all males)
Excl criteria: cardiovascular medication,
known cardiovascular condition,
anticoagulant, dietary supplements with
blood-thinning effect (e.g. fish oil),
medication that affects mental
performance or mood, injury that might
impair performance on test, e.g. stroke.
Background diet: no blood-thinning
supplements.
Regarding compliance: contacted at a
weekly basis to monitor for side effects
and to encourage compliance, unused
capsules returned to laboratory,
compliance ( 75% of capsules used)
was 100% in study 1,
4 non-compliant in Study 2.
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1Table 3b (Continued)
Intermediary of
health effect References
Specification Ginkgo biloba
 dose (PASSCLAIM
criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population (N, age group)
(PASSCLAIM criteria 2A2B)
Information on background diet,
matrix, and compliance?
(PASSCLAIM criteria 2D2F2G)
Cognitive effects/
memory in healthy
people
Elsabagh et al. (83)
[Included in review
Canter]
120 mg ginkgo (Ginkgo
one-a-day tablets), extract LI
1370: 25% flavonoids,
6% total terpene lactones
Placebo-controlled double-blind
design;
exp 1: 1 day (acute treatment), n52
exp 2: 6 weeks (chronic treatment),
n40
University students, 1826 years, n92
excl criteria: use of psychoactive or
anticoagulant medication, alcohol or
drug dependence, pregnancy or
lactation, use of ginkgo, ginseng or soya
isoflavone supplements within a month.
Psychoactive or anticoagulant
medication, supplements excluded.
Long-term memory Persson et al. (84) Not specified, selection from
a database, based on
self-reported regular use of
Ginkgo biloba over a period
of up to 2 years.
Prospective cohort study,
community-dwelling volunteers;
control group 1 (not using suppl.),
control group 2 (suppl. users)
Healthy adult volunteers n40 out of a
database of 3,500 adults (3585 years);
reported currently using, and had been
using Ginkgo biloba regularly during a
longer period of time. n19 used
GB 2 years, mean intake of remaining
was 5.3 months.
Excl: sensory handicaps, organic disease
(e.g. dementia), mental retardation
No information
Bioelectrical effects of
ginkgo
Kennedy et al. (85) Single dose of GK501,
360 mg/day
Double-blind placebo-controlled,
balanced crossover exp,
7 day wash-out
Healthy young volunteers (B40 years),
mean age 26.6 years, 10 female, 5 male
volunteers; in good health; excl criteria:
illicit drug use, use of herbal or
prescribed medication, smoking
 5 cigarettes a day
Abstained from caffeine-containing
products throughout each study day,
abstained from alcohol from 12 h prior
to testing day; compliance monitored
(intern study)
Cognition and mood Hartley et al. (86) Ginkgo 120 mg/day, Ginkgo
one-a-day tablets (LI1370)
Double-blind placebo-controlled
study, 7 days.
Healthy, postmenopausal women,
5365 years n31 excl criteria: use or
HRT in previous 12 months, smoking
 20 cigarettes/day, current illness, use
of psychoactive medication.
Vitamin and mineral use: 10 in ginkgo
group, nine in placebo group; fish oil
supplements eight in each group.
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)Table 3b (Continued)
Intermediary of
health effect References
Specification Ginkgo biloba
 dose (PASSCLAIM
criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population (N, age group)
(PASSCLAIM criteria 2A2B)
Information on background diet,
matrix, and compliance?
(PASSCLAIM criteria 2D2F2G)
Chronic administration Stough et al. (88)
[Included in review
Canter]
Ginkgo biloba (Blackmore’s
Ginkgo biloba Forte,
EGb761, 2000 mg containing
120 mg of active ingredient);
24% flavone glycosides,
6% bilobalide.
Randomized double-blind
placebo-controlled trial, 30 days
61 young healthy volunteers.
Excl criteria: past history of head injury
requiring hospitalization, intellectual
developmental disability, past or current
neurological or psychiatric illness,
inability to speak or understand English,
past or current history of substance
abuse, current pregnancy, currently
taking other putative cognitive
enhancers, current use of any other
medication.
Currently taking other putative
cognitive enhancersexclusion;
compliance monitored.
Memory Moulton et al. (89) LI1370, 120 mg/day Double-blind, placebo-controlled
design; 5 days
Healthy male college students: mean
age 20.5 years n30
No information
Quality of memory Kennedy et al. (39)
[Included in review
Canter]
Acute dose ginkgo 120, 240,
360 mg/day
GK501: 24% flavone glyco-
sides,
6% terpene lactones.
Placebo-controlled multi-dose,
double-blind balanced crossover
design, 1 day.
Undergraduate volunteers (n20), 18
female, 2 male, in good health excl
criteria: medication use, heavy smoking
( 10/day)
Abstained from caffeine-containing
products and alcohol throughout each
study day; compliance monitored
(intern study)
Short-term cognitive
effects
Rigney et al. (90)
[Included in review
Canter]
Four acute doses of ginkgo:
120150240300 mg ginkgo
(LI1370), each treatment was
taken for a period of 2 days,
separated by a 5 day washout
period.
Randomized, double-blind,
placebo-controlled 5-way cross-over
design; at study centre
Asymptomatic volunteers, n31,
3059 years, good physical and mental
health, no concomitant medication
Advised to abstain from alcohol
(compliance checked) and caffeinated
products; subjects stayed at study
centre during the day.
Prevention of cognitive
decline
Snitz et al. (38) EGb761, 120 mg twice daily 5-year randomized double-blind
placebo-controlled trial
Normal elderly or those with mild
cognitive impairment; n3072
Exclusion: dementia at baseline;
neurological or neurodegenerative
disease, higher risk of dementia
(e.g. Parkinson), treatment with
cognitive enhancers, AD medication,
anticoagulants; bleeding disorders,
thrombocytopenia.
All selection criteria were reported in
an earlier study: (91)
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Intermediary of
health effect References
Specification Ginkgo biloba
 dose (PASSCLAIM
criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population (N, age group)
(PASSCLAIM criteria 2A2B)
Information on background diet,
matrix, and compliance?
(PASSCLAIM criteria 2D2F2G)
Prevention of cognitive
decline
Dodge et al. (37) Standardized GB extract,
380 mg daily: at least
6% terpene lactones and
24% flavone glycosides
Study period: 42 months
Randomized, placebo-controlled,
double-blind, 42-month pilot study
Cognitively intact subjects, N118
Inclusion criteria: age 85 or older,
informant available, no subjective
memory complaint, normal memory
function defined by an
education-adjusted score on the
WMS-R, MMSE 23, 6, clinical
dementia Rating0, free from
depressive symptoms (CES-D-10B4).
All participants also received a standard
multivitamin containing 40 IU vitamin E;
the dose of over-the-counter supple-
ments must not be changed during the
course of the trial, the presence and
dose will be recorded; compliance: pill
count
Cognitive function in
healthy, cognitively
intact older adults
Carlson et al. (36) Ginkgo based supplements
containing Ginkgo biloba
(23.2% flavonoid glycosides,
6.7% terpeneolactones,
160 mg/day (a composition
within the ranges used in
EGb761)  68 mg gotu kola,
180 mg DHA, bioflavonoid
concentrate, vitamin A and
beta-carotene
Randomized, double-blind
placebo-controlled parallel design
trial, duration 4 months
Subjects aged 6587 years (n90)
without dementia or depression, not
taking psychoactive medications or
medications or supplements that alter
hemostatis, no history of bleeding
disorders. Other exclusion criteria:
tobacco use, consumption of more than
two alcoholic drinks a day, more than
three servings of fish a week, unstable
heart disease, use of aspirin, NSAIDs,
warfarin.
All participants were given a standard
multivitamin/mineral supplement in
addition to the study product to
minimize confounding factors related to
high supplement use.
Participants needed to maintain
habitual diet
Mild cognitive
impairment; ongoing
trail, baseline data
DeKosky et al. (91) EGb761, 120 mg twice daily 5-year randomized double-blind
placebo-controlled trial
Normal elderly or those with mild
cognitive impairment; n3,072
Exclusion: dementia at baseline;
neurological or neurodegenerative
disease, higher risk of dementia
(e.g. Parkinson), treatment with
cognitive enhancers, AD medication,
anticoagulants; bleeding disorders,
thrombocytopenia.
Restriction on vitamin E intake
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)Table 3b (Continued)
Intermediary of
health effect References
Specification Ginkgo biloba
 dose (PASSCLAIM
criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population (N, age group)
(PASSCLAIM criteria 2A2B)
Information on background diet,
matrix, and compliance?
(PASSCLAIM criteria 2D2F2G)
Cognitive abilities in
healthy adults
Burns et al. (41)
[Included in review
Canter]
Ginkgoforte 120 mg/day
(340 mg): containing per
tablet 40 mg ginkgo extract,
standardized to contain
10.7 mg flavonglycosides
(24%) and 2.7 mg ginkgolides
(6%), 12 weeks
12-week double-blind, fixed-dose,
placebo-controlled, parallel groups
design.
Study 1: healthy older adults (5579
years, males and females) n93.
Study 2: healthy young adults (1843
years) n104 (all males).
Excl criteria: cardiovascular medication,
known cardiovascular condition,
anticoagulant, dietary supplements with
blood-thinning effect (e.g. fish oil),
medication that affects mental
performance or mood, injury that might
impair performance on test, e.g. stroke.
Background diet: no blood-thinning
supplements.
Regarding compliance: contacted at a
weekly basis to monitor for side effects
and to encourage compliance, unused
capsules returned to laboratory,
compliance ( 75% of capsules used)
was 100% in study 1, 4 non-compliant in
Study 2.
Mental functioning,
healthy volunteers
Cieza et al. (92) EGb761 240 mg, 2120 4-week, randomized, double-blind,
placebo-controlled, parallel-group,
monocentric study
66 healthy volunteers, 5065 years,
without age-associated cognitive
impairment excl: concomitant
medication, with exception of
menopausal hormone-replacement
therapy
Intake of concomitant medications
known to affect cognitive function not
permitted; compliance monitored.
Cognitive effects in
healthy older adults
Mix and Crews (34) Ginkgo biloba extract
EGb761, 180 mg/day or
placebo.
Placebo-controlled, double-blind,
randomized trial, 6 weeks
n262, men and women, no memory
impairment,  60y, MMSE ]26
Excl: history of dementia or significant
neurocognitive impairment, active or
clinically sign cardiovascular,
neurological, pulmonary, endocrine,
renal, hepatic, gastrointestinal,
hematological or oncological diseases,
uncontrolled hypertension, learning
disabilities, psychiatric or substance
abuse disorder, history of bleeding
disorder, hemorrhagic stroke,
treatment with anticoagulant or
psychotropic medications. Ginkgo use
before study terminated 28 days for
start.
Treatment with anticoagulant or
psychotropic medications exclusion
criteria; compliance assessed via pill
counts.
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Intermediary of
health effect References
Specification Ginkgo biloba
 dose (PASSCLAIM
criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population (N, age group)
(PASSCLAIM criteria 2A2B)
Information on background diet,
matrix, and compliance?
(PASSCLAIM criteria 2D2F2G)
Acute nootropic effects Nathan et al. (93) Ginkgo biloba 120 mg, 340
mg (Ginkgoforte, 10.7 mg
ginkgo flavonglycosides, 2.7
mg ginkgolides and biloba-
lide)
Repeated measures, double-blind,
placebo-controlled design, 7 day
washout period.
Healthy older subjects, n11 5070
years
Excl: history of dementia, psychiatric
disorders or neurological diseases;
history of bleeding disorders,
gastrointestinal disorders; use of
anticoagulants, antidepressants,
anti-psychotics, anxiolytics, ACE
inhibitors, anti-Parkinson medication or
cognitive enhancing drugs or herbs;
smoking.
Instructed not to consume caffeine
containing food or drinks on testing
days, eat two pieces of toast before
testing.
Learning and memory
in healthy elderly
Solomon et al. (35) Ginkgo biloba extract 40 mg,
three times a day. (Ginkgoba,
EGb761)
6-week randomized, double-blind,
placebo-controlled trial, parallel-
group study
Healthy elderly volunteers, 6082 years
old, n219 (111 ginkgo, 108 placebo),
mini-mental state examination scale
(MMSE) 26.
Excl criteria: history of psychiatric or
neurologic disorder, life-threatening
illness in last 5 years, psychoactive
medication use last 60 days.
No information on background diet;
compliance evaluated by telephone
twice, exclusion of 6 doses were missed
in a 2-week period or didn’t take 3
consecutive doses; envelopes returned.
Activities of Daily living
and mood
Cockle et al. (94) Standardized special extract,
LI1370, 120 mg/day, 4
months
4-month trial, no randomization, not
blind, no placebo
Free living older volunteers, n5028,
mean age 68.9 years (on GB extract
n1,000)
Excl: anticoagulants,
antidepressants
No information, compliance not
monitored
Activities of Daily living
and mood
Trick et al. (95) LI1370: sequal of study
Cockle et al. 94: 120 mg/day,
6 month follow-up
6 month trial (follow-up postal sur-
vey), no randomization, not blind, no
placebo: subjects selected their own
treatment option; four groups: ginkgo
10 months, ginkgo 4 months, ginkgo 6
months, no ginkgo
Free living, older volunteers, n1,570
[of 5,028 in Cockle et al. (94)]
No information; compliance not
monitored
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Intermediary of
health effect References
Specification Ginkgo biloba
 dose (PASSCLAIM
criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population (N, age group)
(PASSCLAIM criteria 2A2B)
Information on background diet,
matrix, and compliance?
(PASSCLAIM criteria 2D2F2G)
Memory improvement: patient studies
Dementia DeKosky et al. (31) EGb761, 120 mg twice daily 5-year randomized double-blind
placebo-controlled trial
Normal elderly or those with mild
cognitive impairment; n3,072
Excl: dementia at baseline; neurological
or neurodegenerative disease, higher
risk of dementia (e.g. Parkinson),
treatment with cognitive enhancers,
AD medication, anticoagulants; bleeding
disorders, thrombocytopenia.
Restriction on vitamin E intake
Dementia and
age-associated memory
impairment
van Dongen et al. (96) Ginkgo biloba special extract
EGb761: 160 mg/day (usual
dose)or 240 mg/day (high
dose)
24-week, randomized, double-blind,
placebo-controlled, parallel-group,
multicenter trial; after 12-weeks
second randomization.
Elderly patients ( 50 years) with
dementia (Alzheimer disease or
vascular dementia) or age-associated
memory impairment (AAMI), impaired
cognitive functioning, objectively or
subjectively, in absence of dementia 
criteria available  n214; mean age:
82.5 years Excl: severe depression,
IQB80, serious co-morbidity, sources
of interference, impermissible
co-interventions (e.g. antipsychotic
drugs, cholinergic therapy)
Use of antipsychotic drugs,
anti-Parkinson medication, neuroleptics,
antidepressants, cholinergic therapy, and
vasoactive drugs in excl criteria;
compliance monitored by pill counting
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Intermediary of
health effect References
Specification Ginkgo biloba
 dose (PASSCLAIM
criterion 12E)
Study designduration
(PASSCLAIM criterion 2)
Study population (N, age group)
(PASSCLAIM criteria 2A2B)
Information on background diet,
matrix, and compliance?
(PASSCLAIM criteria 2D2F2G)
Dementia (Alzheimer’s,
vascular, or mixed) or
age-associated memory
impairment
van Dongen et al. (97)
[Included in review
Birks]
160 or 240 mg Ginkgo biloba
extract per day (EGb761)
24-week randomized double-blind
placebo-controlled study n214.
Efficacy, dose-dependence and
durability evaluated at 12 and 24
weeks. After 12 weeks, ginkgo users
randomized to either continue ginkgo
or go to placebo.
Older persons,  50 years, with de-
mentia (either Alzheimer’s dementia or
vascular dementia, mild to moderate
degree) or age-related memory
impairment (AAMI), n214, mean age
83.9 years
Excl criteria: severe
depression, inadequate level of
pre-morbid intelligence (IQ 80),
serious co-morbidity (in particular
pathological conditions considered
either non-treatable underlying causes
of dementia and cognitive disorders or
sources of interference with trial, like
tumors), co-interventions, drugs with
debilitating influence orn psychical or
cognitive functioning and drugs with a
claimed nootropic action
Drugs with claimed nootropic action
(e.g. antipsychotic drugs, anti-Parkinson
medication, neuroleptics, cholinergic
therapy, antidepressants, and vasoactive
drugs) not permitted; compliance
measured.
Alzheimer and
multi-infarct dementia
Le Bars et al. (29)
[Included in
meta-analysis Birks and
in meta-analysis Oken]
EGb761
120 mg/d (340 mg):
with a 14-day single-blind
placebo run-in period.
Study duration: 52 weeks
52-week randomized double-blind
placebo-controlled parallel-group
multicenter trial
Mildly to severely demented
outpatients with Alzheimer disease or
multi-infarct dementia, diagnosed
according criteria, without other
significant medical conditions, aged
45 (mean age 69), n202
No information; compliance monitored
by pill counts
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Blood circulation: studies in healthy volunteers: insufficient evidence
Boelsma et al. (27) Skin blood flow: assessed on forefoot with laser Doppler
flow meter after 3 weeks. Metabolic fingerprinting: changes
in urinary metabolites measured.
Blood flow after 3 weeks: placebo EGb761 baseline 10.49
6.7; 7.194.4 pB0.01 peak 29.1918.9; 20.9916.8 pB0.01
subjects with highest resting blood flow demonstrated a
decrease after treatment, subjects with average blood flow
no change, subjects with lowest resting blood flow slight
increase after treatment.
Conclusion authors: mean decrease of skin blood flow with
ginkgo use. The data suggest that EGb761 exerts dilatory
or constrictive effects on blood vessels probably according
to the physiological/pathological condition.
Effects of GB on skin blood flow in healthy humans may be
either inhibitory or enhancing which may be related to
individual metabolism; healthy subjects under normal
conditions are functioning close to optimum conditions, so
less or not influenced by improvement.
Santos et al. (25) SPECT
Blood viscosity determined with a rotational viscosimeter
neuropsychological assessment (before and at 8 months)
SPECT: significant differences between the groups in
medial-temporal area, area one basal ganglia, area two
basal ganglia; sign increase of cerebral perfusion in left
hemisphere areas.
Blood viscosity baseline 8 months placebo 4.190.8;
4.890.7 pB0.0001 ginkgo 4.690.6 3.690.6 pB0.0001
sign difference between the groups, pB0.0001
Conclusion authors: significant reduction in blood viscosity
and increased cerebral perfusion in several areas. Appears
to be effective in the treatment of cognitive deficits in older
people.
Mehlsen et al. (81) Measurements of systemic blood pressure and forearm
hemodynamics: at time of inclusion, 3, 6, 9, 12 weeks.
Forearm blood flow measured by venous occlusion
technique; forearm venous capacity: single measurement
after venous occlusion
Forearm blood flow: GB treatment vs. placebo 3 weeks:
3.2 ml vs. 2.2 ml pB0.05 6 weeks: 3.3 ml vs. 2.8 ml pB
0.05 forearm venous capacity: GB treatment vs. placebo 3
weeks: 1.2 ml vs. 0.8 ml pB0.05 6 weeks: 1 ml vs. 0.8 ml
n.s.
Conclusion authors: GB extract is able to dilate forearm
blood vessels causing increments in regional blood flow
without changing blood pressure levels in healthy subjects.
Our study has confirmed the claimed vasodilating effect of
GB extract on peripheral vessels preferentially on the
arterial/arteriolar level.
Comment: No difference made between subjects with
high, average, low resting blood flow, Boelsma et al. (27)
have shown that this could influence the effect.
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Memory improvement: studies in healthy volunteers: insufficient evidence
Burns et al. (41)
[Included in review
Canter]
Study 2: test performed pre- and post-intervention
(12 weeks) cognitive abilities testing
Concept-formation
Raven’s Progressive Matrices
Information
Digit Span
Picture Recognition
Visual matching
Digit Symbol
Memory for Names
Visual-Auditory learning
PASAT
Stroop Color Word test
chronometric testing
‘odd-man-out’ reaction time task (OMO) inspection time
subjective well-being
Profile of Mood States (POMS)
Study 2: withdrawal of 21 participants.
Digit symbol, small effect size d0.17, pB0.10, enhanced
performance in ginkgo group.
No stat sign effects of ginkgo enhancement.
Conclusion authors: positive results limited to a single
cognitive measure, for the older participants only.
Study 2 only males, because ethics committee didn’t
approve inclusion of females at child-bearing age in absence
of any evidence of effects during pregnancy.
No studies that are directly comparable in healthy young
adults, others focused on acute effects of higher doses, or
short term interventions.
Sample sizes were adequate for detecting medium-sized
differential improvement of about half a standard deviation.
Elsabagh et al. (83)
[Included in review
Canter]
Exp 1: subjects tested after 4 h
Exp 2: subjects tested at baseline and 6 weeks
National Adult Reading Test-Revised (NART-R), Hospital
Anxiety and Depression Scale (HAD), Intra Dimensional/
Extra Dimensional set shifting task (IDED), Stockings of
Cambridge (SoC), Spatial working memory (SWM), pattern
recognition memory (PRM), spatial recognition memory
(SRM), word recall, picture recall, paced auditory serial
addition task (PASAT)
Exp 1: significantly improved performance on tests of
sustained attention (PASAT) and PRM, no effects on SRM,
SWM, IDED, SoC.
Exp 2: no sign effects on mood or any of the cognitive test
Comment: PASATdifference at baseline between groups in
Exp 2 is similar to the effect found in exp 1!!
Conclusion authors: in line with literature, acute adminis-
tration improved performance in tests of attention and
memory; however, after 6 weeks no effects in young,
healthy participants, suggesting that tolerance develops.
Persson et al. (84) Eight memory tasks: SPTB free recall of sentences encoded
by enactment; VTB free recall of sentences encoded by
verbal rehearsal; FLUA verbal fluency, FLUPB verbal fluency;
SRB word comprehension; FACRN recognition of faces,
CRSPT cued recall of sentences encoded by enactment;
CRVT cued recall of words encoded by verbal rehearsal
No significant differences between ginkgo group and
control group 1 or control group 2.
Significant effect in the cued recall test of sentences for
control group 2 compared to ginkgo group, in favor of
control group!
No explanation for this result.
Conclusion authors: regular use of Ginkgo biloba during a
long period of time does not enhance memory perfor-
mance in healthy participants with intact cognitive func-
tions.
No well-controlled studies found supporting the claims for
long-term effects on memory.
Comment: unknown dose and frequency of use ginkgo.
Authors assume that recommendations are followed.
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Kennedy et al. (85) Participants assessed 4 h after consuming treatment: EEG
recording
Significant decreases in theta and beta wavebands,
predominantly in frontal scalp areas; ginkgo not associated
with modulation of evoked potentials.
Conclusion authors: study confirms that single dose of
Ginkgo biloba exert effects on cerebral bioelectrical
activity in healthy, young volunteers.
Hartley et al. (86) Cognitive testing at baseline and day 7.
Episodic memory
Weschler Memory Scale-Revised: immediate and delayed
paragraph recall
Delayed Matching-to-Sample test
Long-term episodic memory
Frontal lobe function
Two tests selected from CANTAB
Sustained attention
PASAT
Mood ratings
VAS scales
Episodic memory: ginkgo group sign better in some, but
not all parameters
Frontal lobe function: ginkgo group sign better, but not in
test of planning.
PASAT: ginkgo group sign better
No differences in mood ratings
Conclusion authors: 1 week of ginkgo treatment improved
performance in three of the cognitive tasks. The benefits of
ginkgo on memory and frontal lobe function are modest.
Few ginkgo effect, at marginal levels of significance.
Stough et al. (88)
[Included in review
Canter]
Well-validated neuropsychological tests at baseline and 30
days:
Digit Symbol Substitution Test
Speed of Comprehension Test
Symbol Digit Modalities Test
Digit Span
Trail Making Test
Rey Auditory Verbal Learning Test
Inspection Time
Cognometer Battery of Tests (simple RT and working
memory)
Significant changes of EGb761 compared to placebo for:
Digit Span Backwards (pB0.05)
Working Memory Speed (pB0.05)
Rey Auditory Verbal Learning Test, delay list (pB0.01)
These sign changes indicate significant EGb761 related
improvements specifically in memory processes.
Conclusion authors: EGb761 treatment improves memory
processes, particularly working memory and memory
consolidation. This improvement was clearly evident to
participants throughout the trial, they subjectively noticed
it.
Further research is urgently required to substantiate these
finding in healthy participants.
Moulton et al. (89) Sternberg memory scanning test
vocabulary and digit span subtests
WAIS-R Wechsler Adult Intelligence Scale-Revised reading
span test prose recall test
No significant differences on any tests between ginkgo en
placebo, except for Sternberg Memory Scanning Test.
Conclusion authors: largely ineffective in enhancing
memory
Comment: no baseline measurements, in order to avoid
practice effects; comparability of the two groups assumed
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Kennedy et al. (39)
[Included in review
Canter]
CDR computerised assessment battery prior to dosing and
at 1, 2.5, 4 and 6 h after: word presentation, immediate word
recall, picture presentation, simple reaction time, digit
vigilance task, choice reaction time, spatial working memory,
numeric working memory, word recall, delayed word
recognition, delayed picture recognition, speed of attention,
accuracy of attention, quality of memory, speed of memory.
Dose-dependent improvement of the speed of
attention-factor at 2.5 and 6 h: sign improvement for 240
and 360 mg.
Quality of memory: convincing pattern, performance sign
enhanced for dose 120 mg at 1 and 4 h; 240 mg: same
trend toward sign.
Also, a number of time- and dose-specific changes (both
positive and negative) in performance of the other factors.
Conclusion authors: acute administration of Ginkgo biloba
(240 and 360 mg) is capable of producing a sustained
improvement in attention in healthy young volunteers.
Comment: improvement was not replicated in similar
study in the same population Kennedy (40)
Rigney et al. (90)
[Included in
review Canter]
Test battery conducted pre-dose and hourly.
Range of cognitive outcome measures: immediate word
recall (central loop component of working memory);
Sternberg’s Short Term Memory Scanning Task (articulary
loop component of working memory); stroop color task;
word recall test (immediate and delayed); critical flicker
fusion (CFF); choice reaction time (CRT); digit symbol
substitution taks (DSST); line analog rating scales for
subjective sedation (LARS); leeds sleep evaluation ques-
tionnaire (LSEQ); wrist actigraphy subjective measures of
sedation and sleep
Sternberg: reaction times GBE 120 mg and 300 mg sign.
faster than placebo on both days; most evident for
120 mg: mean decrease in reaction time of 69 ms on day 1,
73.8 ms on day 2; more pronounced in older age group 50
59 years: day 1 decrease of 165.6 ms, day 2 decrease of
172.2 ms.
120 mg produces most evident effects
Conclusion authors: effects on aspects of cognition in
normal healthy volunteers are more pronounced for
memory, particularly working memory, than for arousal or
selective attention; 120 mg produces the most evidence
effect.
Comment by Solomon et al. (35): only improvement found
with 1 dose of ginkgo (120) in oldest group 5059, and only
in one of the multiple tests of memory administered
Comment: subjects were trained on the experimental
measures to a performance plateau to mitigate against
learning effects before proceeding to the study.
Total of 31 volunteers, unknown number in age group 50
59 years.
Comment by ESCOP: the results suggested that
cognition-enhanced effects of the extract are more likely
to be apparent in individuals aged 5059 years, compared
to 3050 years
Snitz et al. (38) Assessments repeated every 6 months
Primary outcome: incidence of all-cause dementia.
Secondary outcomes: rate of cognitive and functional
decline, incidence of cardiovascular and cerebrovascular
events, mortality
Median follow-up 6.1 years.
No differences between GB and placebo group in domain
memory, attention, visuospatial abilities, language,
executive functions, 3MSE, ADAS-Cog.
Conclusion authors: GB did not result in less cognitive
decline in older adults compared to placebo.
Dodge et al. (37) Outcome measures: mild cognitive decline (CDR0t o
CDR0.5), rated by a neurologists, decline in memory
function (10-word Word List Delayed Recall test); adverse
events.
No differences between GB and placebo group in cognitive
decline or memory function decline. After controlling for
medication adherence level, lower risk of cognitive decline
and lower decline in memory function.
Comment: Ginkgo did not effect cognitive function,
because the study was under powered. Information as to
the vehicle and content of the placebo is not provided. The
participants were provided vitamin E tablets; this may have
confounded any potential effect of Ginkgo biloba.T h e r e
was an apparently high rate of (non-hemorrhagic) stroke
among the treatment group.
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Carlson et al. (36) Six standardized cognitive function tests: SF-36 quality of life
questionnaire, platelet function analyzer, monitoring of
adverse events.
87% completed study.
Cognitive function above average at baseline. 1 of 6
cognitive tests significant better after 4 months (p0.03)
in placebo group. No significant differences in quality of life,
platelet function or adverse events
Conclusion authors: the data do not support the use of
Ginkgo biloba supplements to improve cognitive function
or quality of life in healthy adults.
DeKosky et al. (91) Assessments repeated every 6 months
Primary outcome: incidence of all-cause dementia.
Secondary outcomes: rate of cognitive and functional
decline, incidence of cardiovascular and cerebrovascular
events, mortality
Ongoing trial
Burns et al. (41)
[Included in review
Canter]
Study 1: tests performed pre- and post-intervention (12
weeks)
cognitive abilities testing
Woodcock-Johnson Psych-Educational Battery-Revised
Spot-the-Word
Self-Ordered Pointing
chronometric testing
‘odd-man-out’ reaction time task (OMO) inspection time
subjective well-being
Profile of Mood States (POMS)
Study 1: withdrawal of 13 participants.
Longer-term memory, assessed by associational learning
tasks showed improvement with ginkgo:
Long-term storage and retrieval (Glr), part of Woodcock,
d0.52, p0.04
No stat sign difference on any other measure.
Conclusion authors: our result suggests that intermediate-
term storage and retrieval among elderly persons can be
differentially improved by taking ginkgo.
Positive results limited to a single cognitive measure, for
the older participants only.
Sample sizes were adequate for detecting medium-sized
differential improvement of about half a standard deviation.
Cieza et al. (92) Primary and secondary outcome measures at baseline and
day 28.
Primary outcomes: subject’s judgment of own mental health,
general health, Quality of Life on VAS scales
Secondary outcomes: stimulus representation (perception)
Increment Threshold for Visual Stimuli (ITVS) information
processing Digit connection test-G (DCT-G) Worl list test
(WL) emotional evaluation profile of mood states (POMS)
subjective intensity scale-mood (SIS-M) self-rating depres-
sion scale (SDS) action, reaction, volition and decision Finger
tapping test-personal tempo (PT) Finger tapping test-speed
(MT) Auditory choice reaction time (ART) activation/
attention color word test (CWT) incidental learning test
(ILT) subjective intensity scale-tiredness (SIS-T) temporal
mechanism auditory order threshold test (AOT) temporal
reproduction test (TR) sensorimotor synchronization test
(SMS)
Primary outcomes: self-estimated mental health and quality
of life significant better in ginkgo group
Secondary outcomes: stimulus representation: no
differences information processing: no differences
emotional evaluation: no differences action/reaction: in
favor of ginkgo in some aspects of ART, MT activation/
attention: no differences temporal mechanism: in favor of
ginkgo in some TR test
Conclusion authors: no effect on memory, perception,
activation/attention and temporal organization, possibly
due to short time period, low reliability of performed tests
and the study group (enhancement in some mental
functions can be clearly shown in cognitively impaired
patients, but less in healthy volunteers).
Positive effect on general mental health and quality of life of
elderly people after a treatment of 4 weeks.
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Mix and Crews (34) objective, standardized neuropsychological measures at start
and end: Selective Reminding Test (SRT) Wechsler Adult
Intelligence Scale-III Block Design and Digit Symbol Coding
Wechsler Memory Scales (WMS) subjective Follow-up Self-
Report Questionnaire
More improvement on SRT tasks (2 out of 9) compared to
placebo sign. greater improvement on WMS compared to
placebo (but also sign. difference on baseline!!) sign. more
subjects rated themselves as improved.
Conclusion authors: objective and subjective results
provide evidence of the potential efficacy of EGb761 in
enhancing certain neuropsychological/memory processes
of cognitively intact older adults, 180 mg daily for 6 weeks.
Large-scaled clinical trials are needed to examine the
efficacy of EGb761 on the neuropsychological processes of
younger, cognitively intact groups.
Comment: No predefined primary and secondary endpoints,
because of relative absence of previous clinical trials.
Nathan et al. (93) Testing pre- and 90 min post-drug administration (peak
plasma levels): CDR computer test numeric working
memory spatial working memory picture recognition simple
reaction time choice reaction time AVLT (Rey auditory
verbal learning task)
No acute effects of Ginkgo biloba on cognitive functioning. Conclusion authors: no acute nootropic effects of Ginkgo
biloba in healthy older humans.
Comment by authors: no significant effects of 120 mg G.
biloba in healthy older subjects, but other studies find
memory enhancing effects at higher doses (600 mg) or with
more chronic administration.
Solomon et al. (35) Test of learning and memory: California Verbal Learning Test
(CVLT), Logical Memory subscale of the Wechsler Memory
Scale-Revised (WMS-R); Visual Reproduction subscale.
Test of attention and concentration: Digit Symbol subscale of
the Wechsler Adult Intelligence Scale-Revised (WAIS-R), the
Stroop test, the Digit Span (WMS-R); Mental Control
(WMS-R).
Test of expressive language: Controlled Category Fluency
test; Boston Naming Test  Memory Questionnaire for
participant  global evaluation for spouse (Caregiver Global
Impression of Change rating scale).
All tests (with exception of global evaluation) administered
at beginning and end.
Analysis of the modified intent-to treat population: 88%
completed study. No significant differences between
treatment groups on any outcome measure. Also no
difference in the evaluation. In total, 14 different measures
of cognition were evaluated in the study.
Seven of the measures were better in the placebo group,
seven in the ginkgo group. None of the differences were
statistically significant.
Conclusion authors: ginkgo did not enhance performance
on standard neuropsychological tests of learning, memory,
naming and verbal fluency, or attention and concentration.
No measurable benefit in cognitive function in elderly
adults with intact cognitive function, when taken following
the manufacturer’s instructions.
Comments by letters (JAMA, 2003): product is not tested,
exact quantity of the active ingredients remains unknown;
randomization performed by lead investigator, tests
conducted by pill providers, baseline differences for several
of the tests are not discussed.
Comment in ESCOP: use of non-matching placebos
(different dosage forms) criticized.
Cockle et al. (94) B-ADL Scale (at baseline  4 months); self-rating ADL scale;
Line Analog Ratings Scales of mood and sleep (months 14)
Sign differences between ginkgo and control group on all
scales at each time point (14 months)
Conclusion authors: GBE has beneficial effects on areas of
functioning that have implications for quality of life in an
older population.
Comment: subjects not randomized, no placebo, subjective
questionnaires, compliance not measured.
Trick et al. (95) At the end of the 6 months follow-up period: Line Analog
rating scale (LARS), self rating ADL scale
Sign. differences in mean overall LARS and SR-ADL score
between the three treatment groups. Magnitude of
improvement on all scales was related to overall duration
of GBE supplementation.
Conclusion authors: Sign. differences between the groups
suggests that the extract had a demonstrable effect in
improving mood and the self-assessed performance of the
tasks of everyday living.
Comment: no placebo used; no baseline measurements;
sequel to study mentioned above; subjects selected their
own treatment option.
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References Test methods (PASSCLAIM criteria 34)
Effect size (per dosing or time)
(PASSCLAIM criteria 2H5) Remarks
Memory improvement: patient studies
DeKosky et al. (31) Assessments repeated every 6 monthsPrimary outcome:
incidence of all-cause dementia.
Secondary outcomes: rate of cognitive and functional
decline, incidence of cardiovascular and cerebrovascular
events, mortality
Hazard ratio (GB compared to placebo group): all-cause
dementia: 1.12 (0.941.33, p0.21)
Alzheimer disease: 1.16 (0.971.39, p0.11)
Conclusion authors: No effect of GB in reducing incidence
of dementia or Alzheimer disease in elderly individuals
van Dongen et al.
(96)
Outcomes measured after 4, 8, 12, 18, 24 weeks.
Memory and attention
Syndrome Kurz Test (SKT, psychometric functioning);
Clinical Global Impression of change (CGI-2, by nurse),
activities of daily life Nuremberg Gerontopsychological
Rating Scale for Activities of Daily Living (NAI-NAA,
behavioral functioning)
Intervention period: 24 weeks, n123; 79 ginkgo, 44
placebo Ginkgo (both doses) vs placebo, mean change of
scores: SKT:  0.4 (0.91.7) CGI-2: 0.1 (0.30.4)
NAI-NAA: 0.4 (1.91.2) positive small difference in
favor of Ginkgo, but not statistically significant nor clinically
meaningful for dementia subgroup nor AAMI subgroup.
Conclusion authors: the trial results do not support the
view that ginkgo is beneficial for patients with dementia or
age-associated memory impairment.
Comment by authors: AAMI and beginning dementia
patients used, because it is assumed that relative mild
stages of cognitive decline provide for the clearest
manifestations of any effect. The negative results of this
trial cannot fully neutralize the positive results of previous
studies.
van Dongen et al.
(97) [Included in
review Birks]
Assessment of objective measures of cognitive performance,
after 12 and 24 weeks: neuropsychological testing trail-
making speed digit memory span verbal learning clinical
assessment presence and severity of geriatric symptoms
(SCAG), depressive mood (GDS), self-perceived health and
memory status behavioral assessment self-reported level of
instrumental daily life activities
Intention-to-treat analysis: no beneficial effects on
neuropsychological, psychopathological, or behavioral
outcomes for ginkgo group compared to placebo at t24
weeks.
At t12 weeks: 2 ginkgo groups (high-and
low-dose) combined performed better at self-reported
activities of daily life, but worse at self-perceived health
status, compared to placebo.
Conclusion authors: ginkgo is not effective as a treatment
for older people with mild to moderate dementia or age-
associated memory impairment.
Comment: External validity of the study questioned, all
kinds of memory loss were included, heterogeneous
population.
Le Bars et al. (29)
[Included in meta-
analysis Birks and in
meta-analysis
Oken]
Primary outcome measures at baseline, 12, 26, and 52
weeks. Cognitive impairment by Alzheimer’s Disease
Assessment ScaleCognitive subscale (ADASCog) daily
living and social behavior by Geriatric Evaluation by Relative’s
Rating Instrument (GERRI) general psychopathology by
Clinical Global Impression of Change (CGIC)
Intent to treat analysis, EGb761 compared to placebo:
ADAS-Cog 1.4 points better, p0.04 improvement of at
least 4-point: 27% EGb group compared to 14%
placebo-group, p0.005 GERRI score 0.14 points better,
p0.004 improvement 37% EGb group compared to 23%
placebo-group, p0.003 CGIC no significant difference
Conclusion authors: EGb761 is capable of stabilizing and
improving the cognitive performance and the social
functioning of demented patients for 6 months to 1-year.
Comment: only 137 patients completed the trial: 78 EGb
group, 59 placebo-group. comment by van Dongen et al.
(96): Modest improvement of the cognitive performance
and the social functioning of the demented patients
involved. No objective measures of cognitive performance,
cognitive impairment measured.
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Health claim substantiation
The (combined) PASSCLAIM criteria were checked per
health effect, for the selected studies (see Table 3). The
final step of the assessment, PASSCLAIM criterion 6,
weighing of the evidence, is neither worked out in detail
in PASSCLAIM (8), nor in the EFSA guidance docu-
ment (7). In practice, this is done now by EFSA on a
case-by-case basis (2). In our assessment we have used the
WHO criteria (20), which categorizes data into convin-
cing evidence (consistent results from adequately pow-
ered, randomized placebo-controlled trials of the claimed
substance in human subjects representative of the nor-
mal/target population, under normal conditions of use
and assessing endpoints relevant to the claim), probable
evidence (consistent results from small randomized
placebo-controlled trials of the claimed substance or
active ingredients contained therein in sufficient numbers
of human subjects representative of the normal/target
population, under normal conditions of use and assessing
endpoints relevant to the claim and/or human epidemio-
logical studies), possible (or supporting) evidence (con-
sistent results from animal or in vitro studies of the
claimed substance or active ingredients contained therein
and assessing endpoints relevant to the claim) and
insufficient evidence (inconsistent results and/or studies
which do not consider the substance which is the subject
of the claim and/or the target population and/or end-
points relevant to the claim). Below, a summary of the
available evidence per health effect will be given. A
detailed description and comments on individual meta-
analyses, systematic reviews, and individual studies are
given in Table 3.
Health effect 1: improved blood circulation
Treatment of the disease claudication intermittens is one
of the best-known uses of G. biloba. There is a registered
medicine on the market containing G. biloba, Tavonin†,
which is used for patients that don’t respond (enough) to
walking exercise (16). In patients with claudicatio inter-
mittens, a positive effect at a dose of 120 mg/day was seen
in two meta-analyses (21, 22). However, a recent
systematic review that included 739 patients from 14
trials (with different dosage and duration of treatment)
didn’t find a significant effect on walking distance in
people with claudication intermittens (23). Such clinical
studies, however, may not be considered pertinent to a
claim for the general population.
‘Cerebrovascular insufficiency’ is an expression often
used in literature concerning G. biloba. It is an inaccurate
expression that is often used to describe a collection of
symptoms associated with dementia (11) or the effects of
reduced cerebral blood flow in the elderly (24). For the
purpose of this evaluation, therefore, cerebrovascular
insufficiency has been considered a disease. A systematic
review by Kleijnen and Knipschild including patients
with mild to moderate cerebrovascular insufficiency
showed that treatment with 112160 mg/day G. biloba
for 46 weeks was effective for cerebrovascular insuffi-
ciency (24).
An overview of available studies in healthy subjects can
be found in Table 3. Few human studies are available that
have investigated specifically the microcirculation and
improved blood circulation in healthy subjects consuming
G. biloba. Santos et al. (25) did find a lower blood
viscosity (determined with a rotational viscosimeter) in 48
older men that used 80 mg/day G. biloba extract for a
period of 8 months. Another study by the same group
also described a decreased blood viscosity (measured
using ‘Wells-Brookfield Cone/Plate Viscometer’ DV-I) in
25 adult men taking 80 mg GB-STE a day (26). A
randomized double blind placebo-controlled trial with
240 mg/day EGb761 for 3 weeks in 27 older subjects
found a vasoregulation role of G. biloba (27). Unfortu-
nately, the studies described above included different
blood flow parameters, therefore, comparison of the
studies is complicated.
We concluded there was insufficient evidence that GB-
STE use results in improved blood circulation in healthy
subjects.
Health effect 2: improvement of symptoms of old age
To enable scientific evaluation, a claim must include in
the wording some reference to the target population and
the health effect. Current practice within EFSA holds
that such a claim is too vague for evaluation. ‘Symptoms’
and ‘old age’ need to be defined and the wording of the
claim altered to reflect relevant measurable endpoints. If
the claim was submitted through Article 13.1, it would
not be evaluated. If submitted through Article 13.5, the
dossier could be returned to the applicants who in some
cases would be afforded the opportunity to re-word the
claim to enable evaluation subsequent to re-submission.
Health effect 3: improved memory
Studies on Alzheimer and dementia show inconsistent
results for the effect of G. biloba (2831). In the latest
updated version of a systematic review, looking at
cognitive impairment and dementia, it was concluded
that the evidence for a clinically significant benefit of G.
biloba is unreliable (32).
A systematic review on the effects of G. biloba on the
memory of healthy subjects concluded that G. biloba
didn’t improve memory (33). The results of several trials
using G. biloba have been contradictory.
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cognitive endpoints in subjects with mild impairment
(13) or Alzheimer and dementia patients (2831) with
inconsistent results for a beneficial effect of G. biloba.I n
the latest updated version of a systematic review, looking
at cognitive impairment and dementia, it was concluded
that the evidence for a clinically significant benefit of
G. biloba is unreliable (32). Studies employing clinical
samples, however, cannot be considered pertinent to a
claim for the general population. Evidence for benefit in
healthy subjects is mixed.
Alargetrialincluding262healthysubjectsaged60years
and over, observed improved performance on validated
memory testswith GB-STE (180 mg/day, 6 weeks) (34). In
othertrials,G.bilobadidnotenhanceperformanceontests
of memory or other measures of cognitive function (35,
36). A double blind, longitudinal, intervention study by
Dodge et al. (37) found some evidence for improved
memory function in healthy elderly aged 85years (N
118) treated with G. biloba (240 mg/day) compared to
placebo after controlling for compliance. The observed
effect, however, was weak and disappeared when other
variables were controlled. That the subjects were also
administered a multi-vitamin, may have confounded any
effect for ginkgo. The authors do not appear to have
declared the content of the placebo making it difficult to
evaluate the report. The most recent trial, the GEM study,
lookingatcognitivedeclineinhealthyolder adults,didnot
find a difference in cognitive functioning between the G.
biloba and the placebo group (38).
In a small (N20) placebo-controlled study with GB-
STE 240 or 360 mg/day, a positive effect was observed in
young healthy volunteers in improvement in quality of
memory and attention (39). However, this result could
not be replicated in a similar study in the same study
population (40). A double blind controlled study showed
no effect of GB-STE 120 mg/day on the memory of
healthy young males (N104) (41).
In conclusion, there is insufficient evidence to sub-
stantiate the claim that G. biloba can improve memory in
healthy subjects.
Toxicity
In the open literature there are no (animal) data on acute
toxicity, carcinogenicity, reproduction toxicity, terato-
genicity, neurotoxicity or immunotoxicity, but informa-
tion on these toxicological endpoints are available in the
Commission E monograph, ESCOP monograph, the
EMEA report, and a recent NTP study (10, 19, 42).
Reportedly, G. biloba is well absorbed upon oral intake in
animals and human. However, this should be interpreted
with care as G. biloba is an herbal preparation consisting
of many components, which may show interactions.
Indeed, most reports on kinetics focus on known
ingredients of G. biloba such as ginkgolides A and B
and bilobalide.
For GB-STE, low acute toxicity has been reported
for rodents with LD50 values ranging from 1,100
(intravenous, rats and mice) to 7,725 mg/kg body weight
(bw) (oral, mice). A 13-week gavage study in mice and rats
with GB-STE (EGb761 dose levels 0, 65.5 [rats only], 125,
250, 500, 1,000 (rats and mice), and 2,000 (mice only) mg/
kg bw per day) showed an increase in liver weight at all
dose levels tested, and a dose-related increase in hepato-
cytehypertrophyinmaleandfemalemiceatandabove250
mg/kg bw and in male rats at all dose levels. In oral studies
with rats and dogs during 6 months, a dose- and time-
related mild temporary vasodilatation in cranial blood
vessels was observed in dogs dosed at and above 100 mg
GB-STE/kg bw from 35 days on (19).
Although GB-STE was reported not mutagenic in
(among other tests) a Ames test by Commission E 1994
and ESCOP 2003, recently NTP (43) reported a positive
Ames test. An in vivo micronucleus assay was negative for
male mice, whereas for female mice the results were
equivocal. ESCOP (19) reported no carcinogenic effects
in a 2-year study in rats at dose levels of 4, 20, and 100
mg/kg bw. Oral administration of GB-STE to rats (up to
1.6 g/kg bw day) and rabbits (up to 0.9 g/kg bw day) did
not show embryotoxic, teratogenic or reproduction
toxicity effects (19).
GB-STE also contains GAS, to which immunotoxic,
cytotoxic, mutagenic, and carcinogenic properties are
ascribed (4448). As a consequence, a maximum level for
the presence of GAS in the GB-STE was set at 5 mg/kg
(11). However, as not all G. biloba preparations included
in the present study contain GB-STE, maximum levels of
5 mg/kg are not guaranteed, which may pose a health risk
(49). Indeed, Chiu et al. (50) report higher levels (16733
times) than 5 ppm in 13 of 14 G. biloba preparations.
Human studies
Reportedly, G. biloba is generally well tolerated by human
(19, 51), albeit that some mild side effects have been
reported [gastrointestinal complaints, headache, allergic
skin reactions, nausea, dizziness, restlessness, heart pal-
pitation, and weakness (16, 22, 51, 52)]. In addition to
these mild effects, in several case studies side effects have
been reported related to blood platelets, hemorrhage, and
blood coagulation, which is in agreement with the PAF-
inhibiting properties of G. biloba (5361). In these case
reports, reference is made to ‘a ginkgo extract’ or ‘a
ginkgo containing preparation,’ without further specifi-
cations of the G. biloba preparation used. The duration
and dose of intake of G. biloba prior to the reported PAF-
related side effects ranges from 2 weeks to 2 years,
respectively, 80160 mg/day, well within the ‘recom-
mended’ dose range.
Heidi P. Fransen et al.
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data on interactions with drugs are also mainly associated
with drugs involved in the treatment of blood coagulation
and bleeding (53, 6264). The ESCOP monograph (19)
reports that there is no clear evidence for GB-STE on
blood coagulation (alone or in combination with medi-
cines). However, various case reports of interactions with
drugs have been reported (16, 53, 54, 6571). Interactions
of herbal preparations with drugs are particularly rele-
vant for drugs with a narrow therapeutic margin, it can
result in more or stronger side effects or effect on the
bioavailability of the drug (72, 73).
Although a direct causal relationship between G. biloba
intake and observed effects in case studies is lacking (74),
the absence of other risk factors, the PAF-inhibiting
activity of G. biloba, and the disappearance of effects
upon cessation of intake suggest such causality (5961).
The WHO has indicated to be careful with the use of G.
biloba in combination with drugs that affect blood
coagulation or platelet aggregation and to stop G. biloba
use before a diagnostic treatment or an operation (49, 75).
Summarizing, the potential safety issues associated
with G. biloba are severalfold. First, in most literature
reports on G. biloba, the preparation used is not specified.
There is no information on the levels of terpenoids,
flavonoids, and GAS. Animal toxicity studies typically
were performed with GB-STE, whereas in case studies no
specification on the G. biloba preparation is given.
Second, because of the immunotoxic, cytotoxic, carcino-
genic, and genotoxic potential of GAS, the maximum
level of GAS in GB-STE is limited to 5 ppm. However, if
a preparation of G. biloba does not contain the GB-STE,
a higher level of GAS cannot be excluded. Finally, G.
biloba has PAF-antagonist activity, which may result in
effects on platelet aggregation and blood coagulation.
Indeed, there are various case studies reporting hemor-
rhages with intake of G. biloba preparations alone or in
combination with drugs affecting platelet aggregation
and blood coagulation. Moreover, the dose levels of case
reports are within the range of ‘recommended’ dose
levels. Nevertheless, exact dose levels are unknown. As
a result of abovementioned available data, it is not
possible to establish a safe level for intake of G. biloba.
Applicability of the PASSCLAIM criteria
There was insufficient evidence to substantiate the three
selected health claims for G. biloba, when applying the
PASSCLAIM criteria. However, there were some difficul-
tieswhen applying the PASSCLAIM criteria. First, a clear
definition of what sort of study sample constitutes a
healthy target population is lacking. This relates to the
representativeness of the study population for the target
population. Asp and Bryngelsson (3) concluded that
PASSCLAIM is useful for applicants for health claims
and for the agencies that evaluate the evidence. Since
herbal food supplements are intended for healthy persons,
health claims for herbal food supplements have to be
proven in studies performed with healthy persons who are
representative of the target population. However, distinc-
tion between healthy, complaint and illness is not always
clear (definition of ‘a healthy person’ is not clear). For this
analysis we excluded patient studies, which left only a
small number of available studies per health effect. The
first opinions from EFSA seem to support this view (76).
Secondly, it is unclear to which degree a herbal
supplement of an applicant should be identical to the
product used in the human studies. Should they be
exactly the same, or should they contain the same
standardized extract? This study showed that most
studies are performed reportedly using standardized G.
biloba extract, but also that nearly every product found in
the Dutch shops was not in conformity with the label
declaration. When a claim can be substantiated using
those studies, the product that sets the claim should
resemble the standardized extract.
Thirdly, the PASSCLAIM criteria 4 and 5 require
consideration of specific markers, or endpoints, depend-
ing on the type of claim made. Evaluation by an expert
committee is recommended.
Finally, the procedure for weighing the evidence was
not described in detail in the PASSCLAIM project. We
used the WHO criteria to weigh the evidence. In contrast
to the USA, where qualified health claims are allowed
(77), the EU Regulation 1924/2006 was not designed for
supporting qualified health claims. However, qualifica-
tion of the evidence according to the WHO criteria has
proved useful for scientific purposes. The value of such
criteria in consumer communication has not yet been
established. Indeed, in the USA experience, consumers do
not make the anticipated distinction between substan-
tiated and not substantiated (qualified) health claims
(2, 7780). Hence the need for interdisciplinary groups of
expert scientists to monitor and evaluate such claims.
Limitations of the study
There were some limitations of the present study. Firstly,
there was no case with product-specific information,
delivered by a manufacturer, to evaluate. Therefore, a
search of publicly available literature was performed. It is
possible that information is missing, e.g. information
from negative or null trials or unpublished proprietary or
confidential studies. In future, EFSA evaluations will
endeavor to include all available information, including
confidential data, for the substantiation of Article 14 and
13.5 claims. Secondly, regarding the G. biloba products
that were included in this study, the sampling of these
products was random from Dutch shops.
That the search was not exhaustive leaves the possibi-
lity that there were products available for purchase which
were not analyzed and which contained at least the
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(page number not for citation purpose)minimum amount of G. biloba extract. The finding that
the standardized 24% of G. biloba extract is often not
incorporated into the food supplements, nevertheless,
raises doubts as to the efficacy of such products. This
analysis has also implied that it is not possible to establish
a safe level for intake of G. biloba. Review of the science
provided insufficient evidence with which to substantiate
the three claims for G. biloba. In conclusion, the claim G.
biloba and improvement in the symptoms of old age
could not be evaluated. A cause and effect relationship
between G. biloba and improved circulation or memory
has not been established.
Conclusions and recommendations
The main conclusions in this study were:
. Three selected health claims for G. biloba could not be
substantiated.
. Neither safety nor efficacy can be guaranteed at the
recommended daily dose.
. The content of G. biloba containing products often did
not conform to what was declared on the label.
. A multidisciplinary approach is needed to get insight
in the relevant issues for health claim evaluation.
Moreover, the PASSCLAIM criteria need to be devel-
oped in more detail when used for general application on
health claim substantiation for herbal supplements and
there is also a need for clarification of the study
conditions that are required for claim substantiation,
especially with respect to patient studies. A multidisci-
plinary approach is recommended to assess health claims:
analyses of substances typical for G. biloba in the
products and toxicological risk assessment are needed
for a full assessment. This provides a good insight into
the several aspects that are significant for the evaluation
of health claims for herbal substances.
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